By Jeremiah Velasquez, FNP-BC, AGACNP-BC
Founder, Steel City HRT & Weight Loss | Board-Certified Family & Acute Care Nurse Practitioner
NPI: 1841894003

GLP-1 receptor agonist therapy — including semaglutide and tirzepatide — is clinically effective for metabolic weight loss. However, excess adipose tissue converts testosterone into estrogen through aromatization, and GLP-1-driven caloric restriction can accelerate lean muscle loss in men with unaddressed hormonal deficiency. Complete metabolic treatment evaluates and addresses hormone status, cellular recovery, and GLP-1 therapy simultaneously.

Your doctor finally put you on a GLP-1. The appetite suppression was real. The scale moved for the first time in years. You thought this was the reset your metabolism had been waiting for.

Three months in, something is wrong. You're losing weight, but you're exhausted. Your workouts feel harder, not easier. The mental edge you expected to come back hasn't arrived. You're lighter on the scale and heavier in your own head.

This isn't a medication failure. GLP-1 receptor agonists like semaglutide and tirzepatide are legitimate clinical breakthroughs — the STEP 1 trial published in the New England Journal of Medicine demonstrated that semaglutide produced an average body weight reduction of approximately 15% in adults with obesity. The medication is doing its job.

The problem is that it was prescribed in a vacuum. A system that rewards volume over outcomes handed you a tool for metabolic weight loss and sent you home — without evaluating what your hormones were doing, how your muscles would respond to a sustained caloric deficit, or whether your cells had the biological resources to recover. That's not complete medicine. That's a starting point dressed up as a solution.

Why Do GLP-1 Medications Without Testosterone Optimization Leave Men Physically Depleted?

You know something is off. Trust that. The fatigue isn't weakness — it's physiology responding to an incomplete protocol.

Here's the clinical reality: obesity and low testosterone are not separate problems. They are a self-reinforcing cycle. Adipose tissue — body fat — contains an enzyme called aromatase. Aromatase converts testosterone into estradiol, the primary form of estrogen in men. The more excess body fat a man carries, the more active aromatase activity occurs, and the more testosterone gets converted into estrogen. Lower testosterone leads to more fat accumulation, which drives more aromatase activity, which produces even lower testosterone. The cycle feeds itself.

According to a 2007 study published in the Journal of Clinical Endocrinology & Metabolism, a clinically significant inverse relationship exists between body mass index and total testosterone levels in adult men. Obesity is, in many cases, a contributing cause of low testosterone — not simply a coincidence with it.

Now introduce a GLP-1 into this equation. The caloric restriction produced by GLP-1 receptor agonist therapy is real and powerful. But significant caloric deficits — without adequate testosterone levels and protein signaling — can accelerate lean muscle loss. Muscle is metabolically active tissue. It burns calories at rest, maintains insulin sensitivity, and drives physical energy. Losing it in pursuit of fat loss doesn't just hurt performance. It undermines the metabolic outcome GLP-1 therapy was designed to produce.

Three compounding factors are at work. One: testosterone may already be suppressed by excess body fat before GLP-1 therapy begins. Two: the caloric deficit accelerates a catabolic hormonal state. Three: without active hormone monitoring and optimization, the downstream result is persistent fatigue, brain fog, and a body composition shift that feels worse than the number on the scale suggests.

Key takeaway: Obesity and low testosterone are biologically linked through aromatase activity, and GLP-1 therapy without simultaneous hormone evaluation can worsen lean muscle loss and deepen hormonal dysfunction in men who begin treatment already hormonally compromised.

How Do GLP-1 Therapy, Testosterone Optimization, and Peptide Therapy Work Together as a Complete Protocol?

Here's what most people don't know: these three therapeutic tools do not compete. They operate on entirely different biological pathways, and when coordinated correctly under clinical supervision, they address the metabolic picture that each individual tool cannot resolve alone.

Think of it this way. GLP-1 receptor agonist therapy functions like a metabolic thermostat reset. Semaglutide and tirzepatide slow gastric emptying, increase insulin sensitivity, reduce appetite signaling through GLP-1 and GIP receptors, and lower circulating glucose. They target the metabolic environment — the conditions that allowed excess adiposity to develop and persist in the first place.

Testosterone replacement therapy (TRT) — that is, medically supervised testosterone optimization via 503a-compounded injectable or topical testosterone — operates at the hormonal foundation. According to the Endocrine Society's Clinical Practice Guidelines on testosterone therapy, hypogonadal men with total testosterone below 300 ng/dL who receive TRT experience improvements in lean body mass, reductions in fat mass, improved energy, and better insulin sensitivity. TRT doesn't just address drive or libido. It preserves and rebuilds the muscle architecture that GLP-1-driven caloric restriction can erode.

Peptide therapy fills the third gap: cellular recovery and tissue repair. Pharmaceutical-grade peptides — sourced exclusively through licensed 503a compounding pharmacies operating under USP 797 sterility and potency standards — can support growth hormone secretion, lean tissue maintenance, and metabolic recovery during active caloric restriction. Compounds used clinically to stimulate natural growth hormone release, such as CJC-1295 with Ipamorelin, support the anabolic signaling that protects lean mass when the body is in a caloric deficit.

A word on sourcing: the internet is filled with peptides sold as "research-use-only" (RUO) compounds. These are not pharmaceutical preparations. They have never been subjected to USP 797 sterility or potency verification. Contamination, mislabeling, and unknown degradation products are well-documented concerns in the RUO peptide market. If you're using a GLP-1 for a clinical metabolic outcome and sourcing peptides from a gray-market supplier, you're introducing an uncontrolled variable into a protocol that deserves precision. We love a good neighborhood BBQ — but we generally recommend keeping the DIY projects limited to the patio, not your bloodstream.

The STEP 1 trial data is compelling. The GLP-1 mechanism is sound. But combining that mechanism with hormonal stability through TRT and cellular recovery through clinically sourced peptide therapy is what separates metabolic management from metabolic optimization. You can read more about how GLP-1 therapy fits within a broader metabolic protocol on our medical weight loss overview.

Key takeaway: GLP-1 receptor agonist therapy, testosterone replacement therapy, and 503a-compounded peptide therapy each address a distinct biological pathway — and combining them under clinical supervision resolves the metabolic picture that GLP-1 alone was never designed to fully treat.

What Does a Complete GLP-1 and Hormone Optimization Protocol Actually Look Like in Practice?

You've got two options at this point. Stay on a GLP-1 and keep wondering why the energy hasn't returned — watching the scale move while muscle quietly disappears and your hormone panel sits unchecked. Or work with a provider who evaluates the entire system before making a single recommendation

Complete metabolic medicine is a straightforward concept. It is just rarely practiced. Starting with comprehensive labs that include total testosterone, free testosterone, estradiol, SHBG, thyroid function, insulin, and a full metabolic panel, followed by a telehealth consult with a board-certified provider who evaluates both metabolic and hormonal status simultaneously, and ending with a coordinated protocol built around your individual labs and goals — that is what treating the whole patient actually looks like.

The process, in plain terms:

One. A baseline panel that goes beyond glucose and cholesterol — a full hormone workup is the minimum entry point. Two. A telehealth consult with a clinician who maps the metabolic and hormonal picture together, not in separate siloed appointments. Three. An individualized protocol addressing GLP-1 dosing, testosterone optimization, and pharmaceutical-grade peptide support — built around your labs, not a template. Four. Ongoing monitoring through a HIPAA-secure app, with active dose adjustments as your weight loss shifts the hormonal environment over time.

That last point is critical. As body fat decreases through GLP-1 therapy, aromatase activity drops, and testosterone dynamics shift. That is not a set-and-forget situation. It requires intelligent, real-time clinical adjustment.

Key takeaway: A complete metabolic protocol requires comprehensive baseline labs covering both metabolic and hormone status, an individualized coordinated treatment plan, and active clinical monitoring as GLP-1-driven weight loss continues to alter the hormonal environment.

Why Are Patients Choosing Steel City HRT & Weight Loss for Integrated GLP-1 and Hormone Optimization?

I've been on both sides of that table. I've treated patients who came in months into a GLP-1 protocol — exhausted, frustrated, and convinced the medication wasn't working — when the real issue was testosterone that had been suppressed for years and a body that was burning its own muscle to sustain a caloric deficit it was never hormonally equipped to handle. Once the full picture was addressed, everything changed.

Steel City HRT & Weight Loss is LegitScript-certified — the same third-party certification required to run compliant healthcare advertising on Google and Meta. That certification reflects the clinical standard we hold across every program we offer: GLP-1 metabolic optimization, testosterone replacement therapy, and peptide therapy sourced exclusively from licensed 503a compounding pharmacies. Not RUO compounds. Not gray-market powders. Pharmaceutical-grade preparations, compounded under federal sterility and potency standards, prescribed by a licensed provider, and monitored through an individualized protocol.

Steel City is a fully telehealth clinic licensed across ten states — Colorado, Arizona, Washington, Idaho, Maine, Montana, New Hampshire, New Mexico, Arkansas, and Wyoming. No clinic visit required. No waiting room. No referral. The entire process — labs, consult, coordinated protocol, and ongoing management — happens through a HIPAA-secure app, with your provider in your corner between every touchpoint.

As a board-certified nurse practitioner, Jeremiah Velasquez, FNP-BC, AGACNP-BC, built Steel City around one clinical conviction: incomplete medicine produces incomplete results. If the hormone picture isn't evaluated, the GLP-1 results will never tell the full story.

Ready to Start a Complete Protocol? Patients Across All 10 Licensed States Can See a Provider This Week.

You've been on a GLP-1, or you're considering one. The metabolic mechanism is clinically proven. But if hormone status and cellular recovery haven't been evaluated, you don't yet have the full answer — and the fatigue, muscle loss, and stalled progress you're experiencing aren't a coincidence.

Steel City HRT & Weight Loss treats the metabolic and hormonal picture simultaneously, because that's what complete medicine looks like. No waiting rooms. No unanswered questions. No referrals. Patients in Colorado, Arizona, Washington, Idaho, Maine, Montana, New Hampshire, New Mexico, Arkansas, and Wyoming can access a complete metabolic and hormone evaluation without leaving home.

You've got two options. Keep managing weight while the hormone piece goes unaddressed — and keep wondering why the results feel incomplete. Or get the full picture.

Labs, consult, optimization — that easy.

It all starts at steelcity-trt.com.

Frequently Asked Questions

Q: What is the connection between GLP-1 medications and testosterone levels in men? A: GLP-1 receptor agonist therapy — including semaglutide and tirzepatide — drives fat loss, which can reduce aromatase activity and modestly improve the hormonal environment over time. However, men who begin GLP-1 therapy while already hormonally deficient may experience accelerated muscle loss without testosterone support. According to the Endocrine Society, total testosterone below 300 ng/dL warrants clinical evaluation and is common in men with obesity.

Q: Can I take GLP-1 medications and testosterone replacement therapy at the same time? A: Yes. GLP-1 receptor agonist therapy and testosterone replacement therapy (TRT) target entirely different biological pathways and are routinely co-prescribed under clinical supervision. GLP-1 receptor agonists address metabolic function and appetite regulation, while TRT restores hormonal baseline and preserves lean muscle mass. Both require ongoing monitoring, particularly as body composition changes during active weight loss continue to shift the hormonal environment.

Q: How does peptide therapy support a GLP-1 and TRT protocol? A: Pharmaceutical-grade peptides, sourced through licensed 503a compounding pharmacies under USP 797 standards, can support natural growth hormone secretion and tissue repair during periods of caloric restriction. Compounds used clinically for this purpose — such as CJC-1295 with Ipamorelin — help protect lean muscle mass during active fat loss. Only 503a-compounded peptides meet the sterility and potency standards appropriate for clinical use.

Q: What is the difference between RUO peptides and 503a-compounded peptides, and why does it matter? A: Research-use-only (RUO) peptides are unregulated compounds that are not intended or approved for human administration. They are not subject to USP 797 sterility, potency, or purity standards. 503a-compounded peptides are prepared by federally regulated licensed compounding pharmacies under pharmaceutical-grade standards, making them the only appropriate sourcing framework for clinical peptide therapy protocols.

Q: Is it clinically appropriate to start GLP-1 therapy without first checking hormone levels? A: Starting GLP-1 therapy without evaluating testosterone, estradiol, SHBG, and thyroid function leaves significant clinical variables unaddressed. In men with obesity, excess body fat is associated with elevated aromatase activity and suppressed testosterone — factors that can be accelerated by caloric restriction. A comprehensive baseline hormone panel is clinically appropriate at or before the initiation of GLP-1 metabolic optimization therapy.

Q: Is Steel City HRT & Weight Loss available for GLP-1 and hormone optimization in my state? A: Steel City HRT & Weight Loss is a LegitScript-certified telehealth clinic licensed in Colorado, Arizona, Washington, Idaho, Maine, Montana, New Hampshire, New Mexico, Arkansas, and Wyoming. All programs — including GLP-1 metabolic optimization, testosterone replacement therapy, and 503a-compounded peptide therapy — are delivered fully via telehealth. No clinic visit is required to begin.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed provider before beginning any hormone or weight loss therapy. Jeremiah Velasquez, FNP-BC, AGACNP-BC, is a licensed nurse practitioner. Steel City HRT & Weight Loss is a LegitScript-certified telehealth clinic.